This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Obamacare Boosts Health Funds

Can health stocks continue rallying? Probably. The SPDR sector fund has a price-earnings multiple of 18, about the same as the figure for the S&P 500. Many health stocks could deserve a premium at a time when they seem poised to deliver increased revenue and solid dividends.

But after their big rally, the biotech ETFs could be expensive, warns Matt Hougan, president of analytics of "The runup in stocks was awfully quick, and there are not a lot of earnings to support the multiples," he says. Hougan says that for much of the past decade biotech stock stagnated because earnings were scant. Then in recent years, leading companies such as Gilead Sciences (GILD)and Amgen (AMGN) developed solid track records for delivering profits.

Hougan cautions that biotechnology is still in its early stages. Of the 56 companies in SPDR S&P Biotech (XBI), only 15 have earnings, he says. Hougan says that the biotechnology industry seems poised to experience a great earnings surge as more drugs win approval. But investors should be prepared for setbacks along the way.

Biotechnology investors who prefer to focus on the biggest profitable companies should try iShares Nasdaq Biotechnology. Because it weights holdings according to their market capitalizations, the ETF has a big stake in successful companies, including Biogen (BIIB) and Celgene (CELG). SPDR S&P Biotech holds roughly equal stakes in each of its holdings. As a result, the SPDR portfolio includes sizable positions in shaky small companies that have yet to make their marks. Last year, many of the top-performing biotech stocks were profitable stars, and the iShares market-weighted fund outdid SPDR by 7 percentage points.

At the time of publication, the author held no positions in any of the stocks mentioned.

This article represents the opinion of a contributor and not necessarily that of TheStreet or its editorial staff.

2 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
VHT $133.59 -1.40%
XLV $71.81 -0.95%
YHOO $44.13 -0.69%
AAPL $124.25 -0.14%
FB $81.66 -0.67%


DOW 17,698.18 -77.94 -0.44%
S&P 500 2,059.69 -8.20 -0.40%
NASDAQ 4,880.2280 -20.6570 -0.42%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs